Analysts’ Ratings for Johnson & Johnson before Its Q3 Earnings

Analysts’ views on Johnson & Johnson

Johnson & Johnson (JNJ) is scheduled to announce its earnings results for the third quarter on October 16. The healthcare giant has three major divisions—Pharmaceuticals, Medical Devices, and Consumer. Johnson & Johnson has registered consistently strong results over the years despite pricing pressures from the healthcare industry and certain litigation issues. In this article, we’ll look at analysts’ recommendations for JNJ stock ahead of its third-quarter earnings results.

Analysts’ Ratings for Johnson & Johnson before Its Q3 Earnings

On October 9, Reuters surveyed 20 analysts that cover Johnson & Johnson (JNJ) stock. Ten analysts (50.0%) gave “buy” or “strong buy” recommendations for JNJ stock. Nine analysts (45.0%) gave “hold” recommendations on the stock. One analyst gave a “sell” recommendation on Johnson & Johnson stock.

According to these analysts, the consensus target price for JNJ stock is $143.79. This target price implies an upside potential of ~3.2%, based on JNJ’s closing price of $139.39 on October 8.

Peer comparisons

For peers Novartis (NVS), Abbott Laboratories (ABT), and Pfizer (PFE), the average consensus target prices were $98.50, $73.94, and $42.47, respectively, on October 9. These target prices imply 15.5%, 3.5%, and -6.2% returns on an investment in Novartis, Abbott Laboratories, and Pfizer, respectively.

Check out all the data we’ve added to our quote pages. Now you can get a valuation snapshot, earnings and revenue estimates, and historical data as well as dividend info. Take a look!